A Phase 1/2 Study of ABI-009 (Nab-Rapamycin) With Pazopanib (VOTRIENT) in Patients With Advanced Nonadipocytic Soft-Tissue Sarcomas
Phase of Trial: Phase I/II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Pazopanib (Primary) ; Sirolimus (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 25 Oct 2019 Planned End Date changed from 28 Feb 2021 to 28 Feb 2022.
- 25 Oct 2019 Planned primary completion date changed from 28 Feb 2020 to 28 Feb 2021.
- 25 Oct 2019 Status changed from recruiting to suspended.